Skip to main content
. 2022 Aug 26;13(9):1379–1383. doi: 10.1021/acsmedchemlett.2c00319

Figure 1.

Figure 1

PCSK9 impacts LDLC metabolism by regulating LDLR levels. (A) PCSK9 binds LDLR on hepatocyte surfaces, triggering their internalization and degradation by the lysosome. (B) In the presence of a PCSK9 inhibitor (e.g., monoclonal antibody), the prevalence of LDLR increases, leading to improved LDLC metabolism. Adapted with permission from ref (4). Copyright 2022 Mayo Foundation for Medical Education and Research.